Embolization of sacral tumors by Schmidt, Meic H. & Gottfried, Oren N.
Typically, tumors of the sacrum are treated with surgery
or radiotherapy.33 Sacral tumors are challenging to treat
because of the difficulties involved in accessing the lesion,
local recurrences, significant vascularity making a com-
plete resection difficult, resistance to radiotherapy (as seen
in chordomas), and potential for malignant transforma-
tion.33,37 There are several adjuvant therapies available for
treating sacral tumors, including chemotherapy, chemo-
therapy with hyperthermia, and cryosurgery.37 Emboliza-
tion of sacral tumors is a useful adjuvant therapy and aids
in the surgical management of these lesions. Embolization
techniques are used to reduce intraoperative blood loss for
benign, malignant, and metastatic lesions of the sacrum.
These techniques are also used as a primary and definitive
treatment modality for benign lesions, including giant cell
tumors and aneurysmal bone cysts. Embolization can be
effective as a palliative treatment for metastatic lesions
that cause neurological compromise or pain. In general, it
is important for the surgeon to understand that emboli-
zation techniques are a valuable resource for treating sa-
cral tumors. The authors review the literature regarding
the techniques and indications for embolization of sacral
tumors.
TECHNICAL CONSIDERATIONS
There are many highly vascular sacral tumors. If a vas-
cular lesion is suspected based on presentation and imag-
ing, then preoperative angiography should be performed
to characterize the vascular anatomy and to determine if
the lesion would be amenable to embolization.37 Of note,
sacral tumors may have significant collateral circulation,
and tumor neovascular recruitment may induce the for-
mation of an extensive lumbosacral collateral arterial
network. Therefore, knowledge of these interconnections
is imperative prior to performing an embolization pro-
cedure.37
Once the decision is made to proceed with emboliza-
tion, it is important to determine if a proximal arterial oc-
clusion or embolization within the lesion is necessary. Oc-
clusion at the level of the medium-sized vessels allows
collateral circulation to restore flow immediately after em-
bolization. Occlusion of smaller vessels results in slower
constitution of collateral pathways, but there is a potential
for tissue ischemia. Selective delivery of an embolic agent
is desirable to minimize unwanted collateral vessel occlu-
sion and subsequent tissue infarction and necrosis. A
coaxial catheter system is used to achieve a safe selec-
tive catheter position.15 If selective vascular delivery is
not possible, then direct percutaneous puncture techniques
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Abbreviation used in this paper: PVA = polyvinyl alcohol.
may be necessary to obtain a selective embolization place-
ment.5,9 For example, it is possible to use percutaneous
intralesional injections of alcohol embolizing emulsions
when embolization is too risky because the blood supply
of the tumor is close to the vasculature supplying neural
tissue.5,9 
There are several other embolic agents available. The
choice of embolic material is based on the territory to
be embolized, the permanence of occlusion needed, and
the possibilities for selective delivery of an embolic agent
via a transcatheter or direct percutaneous puncture route.
Typically, Gelfoam, PVA particles, and coils are used for
embolization; however, other agents include tissue adhe-
sive, ethanol, and microfibrillar collagen. Generally, em-
bolization is believed to be safe and effective regardless of
the agent used, although it is thought that embolization is
ineffective if proximal occlusion of large vessels is per-
formed without penetrating the distal tumor architecture.28
Gelfoam is a small-particle (40–60 ✁m) embolic agent
administered via a transcatheter technique in cases requir-
ing superselective positioning in the sacral region.37 Its
small particle size makes inadvertent small-vessel occlu-
sion possible; therefore, it should only be used if super-
selective positioning can be achieved.14,37 Gelfoam is a
temporary occlusion; it is degraded by enzymes and reca-
nalization typically occurs between 7 and 10 days.14,15,37
When Gelfoam is used for preoperative embolization, sur-
gery should be performed within 24 hours to prevent
recanalization.13
Polyvinyl alcohol particles are commonly used for dis-
tal embolization to occlude vessels within the tumor.15,24
These particles are inert, water insoluble, nonabsorbable,
and occlude tumor vessels proximal to or at the capillary
bed.24,25,28 They are suspended in nonionic contrast mater-
ial, which allows fluoroscopic visualization of their pro-
gress.24 The particle size ranges from 45 to 500 ✁m.37
Although there is a range in the size of the particles,
Manke, et al.,19 showed that there is no significant differ-
ence in intraoperative blood loss when particles smaller
than or larger than 250 ✁m are used. Gelfoam and PVA
particles may be used in combination. 
Coils are used for proximal occlusion and are useful
because, unlike particles, they do not have the potential
for peripheral dissemination; in addition, they produce
permanent occlusion.14,28 Coils are also used to protect
uninvolved distal vessels.15,19 Coils may be used as the
only occlusive agent or in conjunction with other embolic
material. Of note, Berkefeld, et al.,1 found that coils were
less efficacious for decreasing operative blood loss in spi-
nal column tumors compared with PVA particles or PVA
particles and coils. 
The timing of preoperative embolization is also an im-
portant technical consideration. Generally, it is recom-
mended that embolization be performed as close as possi-
ble to the time of surgery. Typically, minimal blood loss
occurs when surgery is performed within 24 to 48 hours
after embolization.5,13,14,28
TUMOR SELECTION
Benign Lesions. Aneurysmal bone cysts and giant cell
tumors are two benign lesions that may arise in the sacrum
and are difficult to treat. Surgery on giant cell tumors of
the sacrum is technically difficult, and complicated by
extensive hemorrhage and neurological compromise.17
Additionally, radiotherapy produces a limited benefit and
is associated with a risk of malignant change.17 Treatment
is further complicated by the high rate of recurrence of
these tumors.17 Aneurysmal bone cysts of the sacrum are
difficult to manage because of their rapid growth, exten-
sive destruction of bone, high risk of local recurrence,
wide extraosseous tumor masses, and significantly vascu-
lar nature.23
Fortunately, embolization techniques have aided the
treatment of aneurysmal bone cysts and giant cell tumors.
Like malignant lesions, these benign lesions can be em-
bolized prior to resection to reduce blood loss.8,15,23 Em-
bolization can be used to treat pain from aneurysmal bone
cysts and giant cell tumors34 and can also serve as an adju-
vant therapy to surgery or radiotherapy.6,8,10,15,18,23,37 After
other modes of therapy fail in the treatment of unresect-
able giant cell tumors and aneurysmal bone cysts, embol-
ization may be successful.6,8,10 Chuang, et al.,6 treated 10
patients with inoperable giant cell tumors or aneurysmal
bone cysts in whom other treatments had failed. Seven
patients were relieved of pain, in five patients there was
tumor resolution, and, overall, six responded to the thera-
py. It is important to note that these lesions respond to
embolization as a primary and definitive treatment and
there have been many reports in which the procedure
served as an alternative to surgery.6,7,15,17,18,20,30 Lackman,
et al.,17 found that four of five patients with giant cell
tumors of the sacrum treated exclusively with emboliza-
tion experienced resolution of symptoms, arrested tumor
growth, and recurrence. Lin, et al.,18 reported similar re-
sults in 14 of 18 patients with giant cell tumors of the
sacrum treated with serial embolization. De Cristofaro, et
al.,7 and Konya and Szendroi15 found that the majority of
patients with aneurysmal bone cysts responded to single-
treatment embolization with complete resolution of symp-
toms and ossification of the lesion. Konya and Szendroi15
noted remineralization 2 to 4 months after vessel occlu-
sion and reconstruction at 5 to 8 months. Overall, the re-
currence rate after embolization for aneurysmal bone
cysts and giant cell tumors lesions is low, and recurrence
is managed with repeated embolization.7,17
Serial embolization of these lesions is typically per-
formed at 4- to 6-week intervals until symptomatic im-
provement occurs or the tumor’s vascularity disappears.17
Success of embolization is confirmed by postprocedure
angiography, magnetic resonance imaging, or computer-
ized tomography scanning.17 For example, complete ossi-
fication after treatment of aneurysmal bone cysts is con-
sidered a treatment success.15 Reccurrence of symptoms is
followed by a reevaluation with magnetic resonance im-
aging, computerized tomography, or angiography. If there
is an increase in tumor size or evidence of increased vas-
cularity, then embolization therapy is restarted.7 Other
treatment options are used for lesions that do not respond
to embolization. 
There are other benign lesions of the sacrum that are
treated with embolization therapy including osteoid osteo-
ma, osteoblastoma, and hemangiomas.2,4,8,11 Biagini, et
al.,2 and Capanna, et al.,4 noted that preoperative emboli-
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zation is indicated for aggressive osteoid osteomas and
osteoblastomas. Preoperative embolization reduces blood
loss in the surgery of spinal hemangiomas.11
Neural Tumors. Some tumors arising from the neural
elements are vascular and responsive to embolization.
Embolization is useful as a preoperative measure to re-
duce the duration of the procedure and to reduce blood
loss during surgery of presacral schwannomas.29 Addi-
tionally, preoperative embolization has been performed in
a sacral meningioma.12 Shi, et al.,25 used preoperative em-
bolization for several intradural spinal tumors, including a
hemangioblastoma, meningioma, and schwannoma, and
noted decreased intraoperative bleeding and easier resec-
tion due to a defined plane between the tumor and neural
tissue. 
Malignant Lesions. Most primary malignant tumors
of the sacrum demonstrate increased vascularity, although
the most common one, the chordoma, has variable vascu-
larity.27,31 Angiography is useful in determining if a chor-
doma is hypervascular and evaluating whether emboli-
zation would be beneficial as a preoperative measure.36
Wang, et al.,35 performed selective arterial embolization
prior to tumor resection in 15 primary thoracolumbar spi-
nal tumors including malignant schwannomas, chordoma,
fibrous xanthosarcoma, malignant fibrohistocytoma, oste-
osarcoma, Ewing sarcoma, myeloma, and leiomyosarco-
ma. There were satisfactory results after embolization: in
all patients intraoperative blood loss was reduced and
operative time was shortened; there was a clear operative
field for tumor resection. 
Metastatic Tumors. Preoperative embolization of hy-
pervascular metastatic lesions reduces intraoperative
blood loss and improves the surgeon’s ability to resect the
tumor, allowing more aggressive resection. It can also
reduce mass effect, arrest tumor growth, alleviate pain,
and shorten hospital stay.14,24,32 Preoperative embolization
has been shown to reduce intraoperative blood loss for
renal cell carcinoma, thyroid carcinoma, sarcoma, and
metastatic melanoma to the spine.3,13,14,19,21,24,26,28,32 Several
authors have noted reduced blood loss by one third to two
thirds for metastatic spine lesions treated preoperatively
with embolization.1,13,14,19,21 Hess, et al.,14 and Smith, et
al.,28 noted that after embolization, no subsequent surg-
eries had to be terminated because of excessive blood loss.
Even partial embolization can significantly reduce intra-
operative blood loss.19
Embolization has also been used as a primary treatment
for symptomatic relief from metastatic disease. O’Reilly,
et al.,22 treated four patients with transarterial catheter em-
bolization for solitary vertebral metastasis from renal cell
carcinoma, who presented with acute spinal cord or nerve
root compression. All patients experienced neurological
improvement at 24 hours and this improvement lasted for
more than 12 weeks.22 Kuether, et al.,16 noted increased
strength, improved sensation, and decreased spinal cord
compression in a patient with metastatic renal cell carci-
noma to the thoracic spine treated exclusively with embol-
ization. In addition, this patient’s sacral bone metastasis
was successfully treated with embolization. At 5-month
follow up, the patient’s lesions were stable in size and the
patient did not require spinal decompression.  Other met-
astatic spinal lesions, including thyroid carcinoma, can
respond to palliative embolization therapy with resulting
neurological improvement.26
COMPLICATIONS
Most patients experience nausea, emesis, low-grade
fever, and pain after embolization, which usually last 3 to
7 days.10,18,34,37 Ischemic neuropathy can result in motor
and sensory deficits in the pelvis and lower extremities,
and it is a potential complication of any pelvic emboliza-
tion.18,37 Additionally, the neuraxis or the sacral plexus of
nerves can be injured.37 Therefore, care must be taken to
identify and avoid embolization of the neurovascular
anatomy. Rectal ischemia can result from superior hemor-
rhoidal artery embolization.37 Any embolization of sacral
tumors may result in injury to nontargeted tissue including
muscle infarction, injury to the skin, or injury to the colon
or other organs.37
CONCLUSIONS
Embolization is a valuable primary and adjunctive
treatment option for many sacral tumors. Close consulta-
tions among the neurosurgeon, the radiation oncologist,
and the interventionalist will lead to more applications of
embolization techniques, thereby enhancing the treatment
of sacral tumors. 
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